['carcinoma, hepatocellular', 'secondary']
['sorafenib', 'capecitabine', 'oxaliplatin']

        Inclusion Criteria:

          -  Advanced or metastatic hepatocellular carcinoma (HCC) not suitable for surgery or
             various loco-regional therapies.

          -  Diagnosis of HCC confirmed either by cyto-histological confirmation or by non-invasive
             criteria according to the European Association for Study of Liver disease (EASL)
             criteria.

          -  Child-Pugh A or B7 cirrhosis.

          -  Eastern Co-Operative Group (ECOG) performance status ≤ 2.

          -  Life expectancy of ≥ 12 weeks.

          -  Adequate organ function (blood transfusion or use of biologic response modifiers is
             not permitted).

          -  Measurable disease with at least one lesion, which is at least 1 cm in one dimension
             on computed tomography (CT) or magnetic resonance imaging (MRI).

          -  Able and willing to meet all protocol-required treatments, investigations and visits.

          -  Signed written informed consent form.

        Exclusion Criteria:

          -  Prior systemic therapy for advanced HCC.

          -  Central nervous system (CNS) metastasis.

          -  History of liver transplantation.

          -  Peripheral sensory neuropathy with functional impairment before the first cycle of
             treatment.

          -  History of cardiac disease.

          -  Uncontrolled hypertension.

          -  Women who are pregnant or breast-feeding, or women of child-bearing potential who are
             unable or unwilling to practice a highly effective means of contraception.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of study results.
      